HIOC
Chemical compound
- None
- N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-2-oxo-3-piperidinecarboxamide
- 314054-36-9
- 5012758
- 4192105
- JC3KZQ72GW
- Interactive image
- c1cc2c(cc1O)c(c[nH]2)CCNC(=O)C3CCCNC3=O
InChI
- InChI=1S/C16H19N3O3/c20-11-3-4-14-13(8-11)10(9-19-14)5-7-18-16(22)12-2-1-6-17-15(12)21/h3-4,8-9,12,19-20H,1-2,5-7H2,(H,17,21)(H,18,22)
- Key:ZIMKJLALTRLXJO-UHFFFAOYSA-N
HIOC is a small-molecule agent which acts as a selective TrkB receptor agonist (active at at least 100 nM; prominent activation at 500 nM).[1][2][3] It was derived from N-acetylserotonin (NAS).[2][3][4] Relative to NAS, HIOC possesses greater potency and a longer half-life (~30 min or less for NAS in rats, while HIOC is still detectable up to 24 hours after administration to mice; ~4 hour half-life for HIOC in mouse brain tissues).[2][3] It is described as producing long-lasting activation of the TrkB receptor and downstream signaling kinases associated with the receptor.[2] HIOC is systemically active and is able to penetrate the blood-brain-barrier.[2] In animal studies, HIOC was found to robustly protect against glutamate-induced excitotoxicity, an action which was TrkB-dependent.[3]
A chemical synthesis of HIOC was published in 2015.[5]
See also
References
- ^ Longo FM, Massa SM (July 2013). "Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease". Nature Reviews. Drug Discovery. 12 (7): 507–525. doi:10.1038/nrd4024. PMID 23977697. S2CID 33597483.
- ^ a b c d e Iuvone PM, Boatright JH, Tosini G, Ye K (2014). "N-Acetylserotonin: Circadian Activation of the BDNF Receptor and Neuroprotection in the Retina and Brain". Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology. Vol. 801. pp. 765–771. doi:10.1007/978-1-4614-3209-8_96. ISBN 978-1-4614-3208-1. PMC 4069859. PMID 24664769.
- ^ a b c d Shen J, Ghai K, Sompol P, Liu X, Cao X, Iuvone PM, Ye K (February 2012). "N-acetyl serotonin derivatives as potent neuroprotectants for retinas". Proceedings of the National Academy of Sciences of the United States of America. 109 (9): 3540–3545. Bibcode:2012PNAS..109.3540S. doi:10.1073/pnas.1119201109. PMC 3295250. PMID 22331903.
- ^ Tosini G, Ye K, Iuvone PM (December 2012). "N-acetylserotonin: neuroprotection, neurogenesis, and the sleepy brain". The Neuroscientist. 18 (6): 645–653. doi:10.1177/1073858412446634. PMC 3422380. PMID 22585341.
- ^ Setterholm NA, McDonald FE, Boatright JH, Iuvone PM (June 2015). "Gram-scale, chemoselective synthesis of N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC)". Tetrahedron Letters. 56 (23): 3413–3415. doi:10.1016/j.tetlet.2015.01.167. PMC 4445863. PMID 26028783.
- v
- t
- e
- Agonists: Angiopoietin 1
- Angiopoietin 4
- Antagonists: Angiopoietin 2
- Angiopoietin 3
- Kinase inhibitors: Altiratinib
- CE-245677
- Rebastinib
- Antibodies: Evinacumab (against angiopoietin 3)
- Nesvacumab (against angiopoietin 2)
| EGF (ErbB1/HER1) |
|
|---|---|
| ErbB2/HER2 |
|
| ErbB3/HER3 |
|
| ErbB4/HER4 |
|
| FGFR1 | |
|---|---|
| FGFR2 |
|
| FGFR3 | |
| FGFR4 | |
| Unsorted |
|
- Agonists: Fosgonimeton
- Hepatocyte growth factor
- Potentiators: Dihexa (PNB-0408)
- Kinase inhibitors: Altiratinib
- AM7
- AMG-458
- Amuvatinib
- BMS-777607
- Cabozantinib
- Capmatinib
- Crizotinib
- Foretinib
- Golvatinib
- INCB28060
- JNJ-38877605
- K252a
- MK-2461
- PF-04217903
- PF-2341066
- PHA-665752
- SU-11274
- Tivantinib
- Volitinib
- Antibodies: Emibetuzumab
- Ficlatuzumab
- Flanvotumab
- Onartuzumab
- Rilotumumab
- Telisotuzumab
- Telisotuzumab vedotin
| IGF-1 |
|
|---|---|
| IGF-2 |
|
| Others |
- Antagonists: ALE-0540
- Dexamethasone
- EVT-901 (SAR-127963)
- Testosterone
- Antibodies: Against NGF: ABT-110 (PG110)
- ASP-6294
- Fasinumab
- Frunevetmab
- Fulranumab
- MEDI-578
- Ranevetmab
- Tanezumab
- Aptamers: Against NGF: RBM-004
- Decoy receptors: LEVI-04 (p75NTR-Fc)
- Agonists: Becaplermin
- Platelet-derived growth factor (A, B, C, D)
- Kinase inhibitors: Agerafenib
- Avapritinib
- Axitinib
- Crenolanib
- Imatinib
- Lenvatinib
- Masitinib
- Motesanib
- Nintedanib
- Pazopanib
- Radotinib
- Quizartinib
- Ripretinib
- Sunitinib
- Sorafenib
- Toceranib
- Antibodies: Olaratumab
- Ramucirumab
- Tovetumab
| GFRα1 |
|
|---|---|
| GFRα2 |
|
| GFRα3 |
|
| GFRα4 |
|
| Unsorted |
|
- See here instead.
| TrkA |
|
|---|---|
| TrkB |
|
| TrkC |
|
- Agonists: Placental growth factor (PGF)
- Ripretinib
- Telbermin
- VEGF (A, B, C, D (FIGF))
- Allosteric modulators: Cyclotraxin B
- Kinase inhibitors: Agerafenib
- Altiratinib
- Axitinib
- Cabozantinib
- Cediranib
- Fruquintinib
- Lapatinib
- Lenvatinib
- Motesanib
- Nintedanib
- Pazopanib
- Pegaptanib
- Rebastinib
- Regorafenib
- Semaxanib
- Sorafenib
- Sunitinib
- Toceranib
- Tivozanib
- Vandetanib
- WHI-P 154
- Antibodies: Alacizumab pegol
- Bevacizumab
- Icrucumab
- Ramucirumab
- Ranibizumab
- Decoy receptors: Aflibercept
- Additional growth factors: Adrenomedullin
- Colony-stimulating factors (see here instead)
- Connective tissue growth factor (CTGF)
- Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
- Erythropoietin (see here instead)
- Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
- Glia maturation factor (GMF)
- Hepatoma-derived growth factor (HDGF)
- Interleukins/T-cell growth factors (see here instead)
- Leukemia inhibitory factor (LIF)
- Macrophage-stimulating protein (MSP; HLP, HGFLP)
- Midkine (NEGF2)
- Migration-stimulating factor (MSF; PRG4)
- Oncomodulin
- Pituitary adenylate cyclase-activating peptide (PACAP)
- Pleiotrophin
- Renalase
- Thrombopoietin (see here instead)
- Wnt signaling proteins
- Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
